ES2194998T3 - Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico. - Google Patents

Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.

Info

Publication number
ES2194998T3
ES2194998T3 ES96923511T ES96923511T ES2194998T3 ES 2194998 T3 ES2194998 T3 ES 2194998T3 ES 96923511 T ES96923511 T ES 96923511T ES 96923511 T ES96923511 T ES 96923511T ES 2194998 T3 ES2194998 T3 ES 2194998T3
Authority
ES
Spain
Prior art keywords
progression
neuropathic pain
formulations
inhibit
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96923511T
Other languages
English (en)
Spanish (es)
Inventor
Gary Arthur Amstutz
Stephen Scott Bowersox
Kishorchandra Gohil
Peter Isadore Adriaenssens
Ramasharma Kristipati
Theresa Gadbois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2194998T3 publication Critical patent/ES2194998T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Saccharide Compounds (AREA)
ES96923511T 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico. Expired - Lifetime ES2194998T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia

Publications (1)

Publication Number Publication Date
ES2194998T3 true ES2194998T3 (es) 2003-12-01

Family

ID=27052304

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96923511T Expired - Lifetime ES2194998T3 (es) 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.
ES03007342T Expired - Lifetime ES2283671T3 (es) 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03007342T Expired - Lifetime ES2283671T3 (es) 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico.

Country Status (13)

Country Link
EP (2) EP1336409B1 (enExample)
JP (1) JP2838073B2 (enExample)
AT (2) ATE235914T1 (enExample)
AU (1) AU695166B2 (enExample)
CA (1) CA2224795C (enExample)
DE (3) DE69637021T2 (enExample)
DK (2) DK1336409T3 (enExample)
ES (2) ES2194998T3 (enExample)
FR (1) FR05C0027I2 (enExample)
LU (1) LU91181I2 (enExample)
NL (1) NL300201I2 (enExample)
PT (2) PT835126E (enExample)
WO (1) WO1997001351A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
JP2002509080A (ja) * 1998-02-20 2002-03-26 シンジェンタ リミテッド グラモストラ・スパチュラタの毒から得られる鎮痛性ペプチドおよびその使用
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
WO2004050690A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004028678D1 (de) 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
JP2007507538A (ja) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
US8673856B2 (en) * 2006-11-04 2014-03-18 Anygen Co., Ltd. Omega conotoxins
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
KR20220042487A (ko) 2008-12-31 2022-04-05 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP6392754B2 (ja) 2012-08-21 2018-09-19 アーデリクス，インコーポレーテッド 体液貯留又は塩過負荷に関係する疾患及び消化管疾患の治療におけるｎｈｅ仲介の逆輸送を阻害するための化合物並びに方法
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
BR112015025805A2 (pt) 2013-04-12 2017-07-25 Ardelyx Inc compostos de ligação de nh3 e métodos para inibir o transporte de fosfato
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
BR112019013963A2 (pt) 2017-01-09 2020-04-28 Ardelyx Inc inibidores de antiporte mediado por nhe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
WO1993013128A1 (en) * 1991-12-30 1993-07-08 Neurex Corporation Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
AU6400296A (en) 1997-01-30
DE69637021D1 (de) 2007-05-24
EP1336409A1 (en) 2003-08-20
DE69627153D1 (de) 2003-05-08
DE69627153T2 (de) 2003-12-04
EP0835126A1 (en) 1998-04-15
NL300201I2 (nl) 2006-02-01
EP1336409B1 (en) 2007-04-11
JP2838073B2 (ja) 1998-12-16
DE69637021T2 (de) 2008-01-10
DE122005000043I1 (de) 2006-06-29
DE122005000043I2 (de) 2006-08-03
FR05C0027I2 (enExample) 2006-12-29
PT1336409E (pt) 2007-06-29
EP0835126B1 (en) 2003-04-02
CA2224795A1 (en) 1997-01-16
CA2224795C (en) 2001-04-03
AU695166B2 (en) 1998-08-06
WO1997001351A1 (en) 1997-01-16
HK1058146A1 (en) 2004-05-07
LU91181I2 (fr) 2005-09-06
PT835126E (pt) 2003-07-31
ATE359086T1 (de) 2007-05-15
FR05C0027I1 (enExample) 2005-08-12
ES2283671T3 (es) 2007-11-01
JPH09104634A (ja) 1997-04-22
DK1336409T3 (da) 2007-08-13
DK0835126T3 (da) 2003-07-14
ATE235914T1 (de) 2003-04-15
NL300201I1 (nl) 2005-09-01

Similar Documents

Publication Publication Date Title
ES2194998T3 (es) Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.
ITMI951278A0 (it) Formulazioni di analoghi dell'insulina
TR199600498A2 (tr) S(+)-ibuprofen'in oral formülasyonlari.
CA2222676A1 (en) New pharmaceutical composition with anaesthetic effect
MY115662A (en) Novel compounds with analgesic effect
IL114035A0 (en) Antiseptic dentifrice
BR9712491A (pt) Composições cosméticas
CA2219502A1 (en) Methods and formulations for modulating the human sexual response
MX9207317A (es) Composiciones desensibilizadoras de la dentina.
FR2685869B1 (fr) Compositions therapeutiques a base d'inhibiteurs mixtes de la no synthase et de la cyclooxygenase.
FR2757370B1 (fr) Plaque perfectionnee d'osteosynthese femorale
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
BR9808302A (pt) O uso de levobupivacaìna na cirurgia pediátrica
EP0631772A3 (en) Agent containing retinoid.
IT8447621A0 (it) Composizioni cosmetiche destinate a migliorare le proprieta' meccaniche delle unghie umane e metodo di trattamento delle unghie per mezzo di queste composizioni
FR2760635B1 (fr) Procede de preparation d'une composition cosmetique a base de platre et composition cosmetique ainsi obtenue
HU9800623D0 (en) Oral application of "(+)-o-demethyl-tramadol as analgesic active component
AU3992897A (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
KR970000226A (ko) S-이부프로펜의 경구용 제형
HUP9800272A2 (hu) Penciclovir alkalmazása emberi herpeszvírus-8 kezelésére
FR2746315B1 (fr) Melange therapeutique pour massages a base d'huiles essentielles
AU124671S (en) Elongate frame extension
TH6799S1 (th) เก้าอี้
IT1286255B1 (it) Caramella all'aceto balsamico
TH11873S1 (th) แปรงสีฟัน